Economic Evaluation in Genomic and Precision Medicine

Provides an in-depth examination of essential concepts, protocols and applications of economic evaluation in genomic and precision medicine

Christina Mitropoulou (Volume editor), Sarah Wordsworth (Volume editor), James Buchanan (Volume editor), George P. Patrinos (Volume editor)

9780128133828, Elsevier Science

Paperback, published 24 April 2023

170 pages
23.4 x 19 x 1.2 cm, 0.45 kg

Economic Evaluation in Genomic and Precision Medicine provides an in-depth examination of essential concepts, protocols and applications of economic evaluation in genomic and precision medicine. Contributions from leading international medical geneticists and health economists compile new ways to effectively assess the costs and outcomes of different genomic care pathways, implement cost-effective medical interventions, and enhance the value of genomic and precision healthcare. Foundational chapters and discipline-specific case studies cover topics ranging from the economic analysis of genomic trial design, to health technology assessment of next-generation sequencing, ethical aspects, economic policy in genomic medicine, and pricing and reimbursement in clinical genomics.

1. Introduction to economic evaluation in health sciences
2. Foundations of pharmacogenomics and personalized medicine
3. Economic evaluation of genome-guided treatment in oncology
4. Economic evaluation of rare diseases and the diagnostic odyssey
5. Economic analysis of pharmacogenetic testing for HLA-based adverse drug reactions
6. Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor proliferation of genomics and genetic testing
7. Theoretical models for economic evaluation in genomic and personalized medicine
8. Using big data in economic evaluations in genomics: Challenges and opportunities
9. Assessing the stakeholder environment and views towards implementation of personalized medicine in a healthcare setting
10. Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions

Subject Areas: DNA & Genome [PSAK1], Genetics [non-medical PSAK]